Sanofi (SNY) Earnings History
Earnings Pressure27 years of earnings data (1999–2025) · 5-year EPS trend is negative
Loading earnings history...
Sanofi (SNY) Earnings Overview
As of June 21, 2026, Sanofi (SNY) reported trailing twelve-month net income of $7.81B, reflecting -7.3% year-over-year growth. The company earned $3.20 per diluted share over the past four quarters, with a net profit margin of 16.7%.
Looking at the long-term picture, SNY's 5-year EPS compound annual growth rate (CAGR) stands at -16.2%, signaling declining earnings. The company achieved its highest annual net income of $12.29B in fiscal 2020.
Sanofi maintains industry-leading profitability with a gross margin of 72.3%, operating margin of 13.6%, and net margin of 16.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including NVO ($121.96B net income, 33.1% margin), AZN ($10.39B net income, 17.5% margin), NVS ($13.53B net income, 25.6% margin), SNY has room to improve margins relative to the peer group. Compare SNY vs NVO →
SNY Earnings vs Peers
Earnings metrics vs comparable public companies
SNY Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.81B | +40.5% | $6.34B | $2.03 | 16.7% | 13.6% |
| 2024 | $5.56B | +3.0% | $7.25B | $2.19 | 12.6% | 16.4% |
| 2023 | $5.40B | -35.5% | $6.96B | $2.15 | 13.0% | 16.7% |
| 2022 | $8.37B | +34.5% | $10.16B | $3.18 | 20.6% | 25.1% |
| 2021 | $6.22B | -49.4% | $8.13B | $2.49 | 15.9% | 20.7% |
| 2020 | $12.29B | +346.4% | $14.11B | $4.91 | 32.9% | 37.8% |
| 2019 | $2.75B | -36.0% | $3.05B | $1.14 | 7.3% | 8.1% |
| 2018 | $4.31B | -48.8% | $4.68B | $1.73 | 12.1% | 13.1% |
| 2017 | $8.42B | +78.7% | $5.80B | $3.36 | 23.2% | 16.0% |
| 2016 | $4.71B | +9.8% | $6.53B | $1.83 | 13.6% | 18.8% |
| 2015 | $4.29B | -2.3% | $5.62B | $1.64 | 12.3% | 16.1% |
| 2014 | $4.39B | +18.1% | $6.06B | $1.67 | 13.7% | 19.0% |
| 2013 | $3.72B | -24.0% | $4.98B | $1.41 | 11.9% | 15.9% |
| 2012 | $4.89B | -13.4% | $6.43B | $1.84 | 13.6% | 17.9% |
| 2011 | $5.65B | +3.3% | $5.86B | $2.15 | 16.1% | 16.7% |
| 2010 | $5.47B | +3.8% | $6.54B | $2.10 | 16.1% | 19.2% |
| 2009 | $5.26B | +36.7% | $6.37B | $2.02 | 17.1% | 20.7% |
| 2008 | $3.85B | -26.8% | $4.39B | $2.75 | 13.4% | 15.2% |
| 2007 | $5.26B | +31.4% | $5.91B | $1.95 | 18.0% | 20.2% |
| 2006 | $4.01B | +77.6% | $5.73B | $1.48 | 13.6% | 19.4% |
| 2005 | $2.26B | +13.7% | $4.75B | $0.84 | 7.9% | 16.7% |
| 2004 | $1.98B | -4.2% | $2.90B | $1.09 | 12.6% | 18.4% |
| 2003 | $2.07B | +17.7% | $3.07B | $1.48 | 25.8% | 38.2% |
| 2002 | $1.76B | +11.0% | $2.62B | $1.21 | 23.6% | 35.1% |
| 2001 | $1.58B | +60.9% | $2.11B | $1.09 | 24.4% | 32.5% |
| 2000 | $985M | +57.6% | $1.58B | $0.68 | 16.5% | 26.4% |
| 1999 | $625M | - | $971M | $0.43 | 11.7% | 18.1% |
Download Data
Export SNY earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into SNY consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
27+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SNY — Frequently Asked Questions
Quick answers to the most common questions about buying SNY stock.
What is SNY earnings per share (EPS)?
SNY trailing twelve-month (TTM) diluted EPS is $3.20, reflecting -7.3% year-over-year growth. The 5-year EPS CAGR is -16.2%. Complete EPS history from 1999 to 2025 is available in the table on this page.
What is Sanofi's net income?
Sanofi (SNY) trailing twelve-month net income is $7.8B as of 2025. Earnings declined -7.3% year-over-year. Sanofi has been profitable for 27 consecutive years.
Is SNY profitable?
Yes, SNY is profitable with a TTM net income of $7.8B and a net profit margin of +16.7%. Sanofi has generated profits for 27 consecutive years.
What is SNY's earnings growth rate?
SNY compound annual EPS growth rates (CAGR): 1-Year: -7.3%, 3-Year: -13.9%, 5-Year: -16.2%, 10-Year: +2.2%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1999 to 2025.
What are SNY's profit margins?
Sanofi net profit margin is +16.7%, operating margin is +13.6%, and gross margin is +72.3%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +10.4%.
Is SNY growing earnings?
SNY earnings are declining — EPS fell -7.3% year-over-year. TTM net income dropped to $7.8B. This contrasts with the 5-year CAGR of -16.2%.
What was SNY's best earnings year?
Sanofi's highest annual net income on record is $12.3B, achieved in fiscal year 2020. Earnings history on this page spans 1999 to 2025 and includes all annual and quarterly figures.
What were SNY's earnings last quarter?
SNY's most recent reported quarter was Q4 2025. Net income was $-801M with diluted EPS of $-1.46. For a full breakdown of all quarters, see the quarterly earnings table on this page.